NASDAQ: DMAADrugs Made In America Acquisition Revenue
Drugs Made In America Acquisition revenue was $0.00 for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, DMAA annual revenue was $0.0, with N/A growth year-over-year.
DMAA revenue history
Current Revenue
$0.0
Current Earnings
$5.9M
Current Profit Margin
0%
Be the first to know when DMAA announces revenue.
DMAA Revenue History By Year
| DMAA Yearly Revenue | DMAA Revenue | DMAA Change | DMAA Revenue Growth |
|---|---|---|---|
| 2025-12-31 | $0.00 | N/A | N/A |
| 2024-12-31 | $0.00 | N/A | N/A |
Drugs Made In America Acquisition Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.